Overall mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in overall mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in infection‐related mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics may leads to lower people hospitalized for > 10 days compared with antibiotics alone (low certainty).
1 finding from 1 review
Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in duration of grade IV neutropenia (lower values signify better… compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to recovery from fever (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to recovery from fever (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to withdrawal from ATB (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to withdrawal from ATB (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Deep vein thrombosis · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in deep vein thrombosis compared with antibiotics alone (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to lower overall survival (low certainty).
1 finding from 1 review
Intervention not reported
Toxic death · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Adverse effects · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to higher quality of life (low certainty).
1 finding from 1 review
All cause mortality · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower all cause mortality compared with placebo or no intervention (high certainty).
1 finding from 1 review
Febrile patients and episodes · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics probably leads to lower febrile patients and episodes compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Bacteraemia · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower bacteraemia compared with placebo or no intervention (high certainty).
1 finding from 1 review
All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Febrile patients and episodes · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Bacteraemia · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to lower febrile neutropenia Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Injection‐site reaction Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to higher injection‐site reaction Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review